Education and Training
Gastrointestinal STRING Test With Oral Immunotherapy
This STRING study will examine markers of esophageal inflammation using a minimally-invasive testing device, the esophageal string test (EST). The primary objective is to determine the effect of omalizumab (Xolair) and dupilumab (Dupixent) on markers of eosinophilic inflammation in the esophagus of subjects treated with omalizumab-facilitated mOIT(mult-allergen oral immunotherapy) and/or mOIT with concurrent dupilumab.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Entero-tracker
Eligibility
Inclusion Criteria: • Participants, aged 5-55 years enrolled in the parent COMBINE trial
- Able to swallow the EST.
Exclusion Criteria: • Allergy to, or inability to ingest, gelatin
-
Ages Eligible for Study
5 Years - 55 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting